该五款新产品包括：米美欣®(羟考酮纳洛酮缓释片)、瑞百莱®(棕榈酸帕利哌酮注射液(Ⅱ))首次纳入国 家医保药品目录；赞必佳®(注射用芦比替定)成功入选商保创新药目录；百拓维®(注射用戈舍瑞林微 球)、瑞可妥®(注射用利培酮微球(Ⅱ))顺利续约，继续被纳入国家医保药品目录。 本文源自：智通财经网 智通财经获悉，绿叶制药(02186)涨近3%，截至发稿，涨2.66%，报3.09港元，成交额837.51万港元。 消息面上，12月7日，绿叶制药发布公告，集团共有五款新产品成功纳入由国家医疗保障局发布的《国 家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(国家医保药品目录)或《商业健康保险创新 药品目录(2025年)》(商保创新药目录)。 ...

Core Viewpoint - Green Leaf Pharmaceutical (02186) saw a nearly 3% increase in stock price, currently at HKD 3.09, with a trading volume of HKD 8.3751 million, following the announcement of five new products being included in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] Group 1 - The five new products include: - Mimesin® (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug Catalog [1] - Zanbija® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1] - Baituowei® (Injectable Goserelin Microspheres) and Ruiketuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug Catalog [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186) has successfully included five new products in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin® (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List [1] - Zanbija® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituowei® (Injectable Goserelin Microspheres) and Ruiketuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug List [1]